- Home
- ATYR vs POLE Comparison
ATYR vs POLE Comparison
Compare ATYR & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- POLE
- Stock Information
- Founded
- ATYR 2005
- POLE 2024
- Country
- ATYR United States
- POLE United States
- Employees
- ATYR N/A
- POLE N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- POLE
- Sector
- ATYR Health Care
- POLE
- Exchange
- ATYR Nasdaq
- POLE NYSE
- Market Cap
- ATYR 306.2M
- POLE 299.8M
- IPO Year
- ATYR 2015
- POLE 2024
- Fundamental
- Price
- ATYR $4.73
- POLE $10.32
- Analyst Decision
- ATYR Strong Buy
- POLE
- Analyst Count
- ATYR 6
- POLE 0
- Target Price
- ATYR $18.60
- POLE N/A
- AVG Volume (30 Days)
- ATYR 1.5M
- POLE 70.8K
- Earning Date
- ATYR 05-07-2025
- POLE 01-01-0001
- Dividend Yield
- ATYR N/A
- POLE N/A
- EPS Growth
- ATYR N/A
- POLE N/A
- EPS
- ATYR N/A
- POLE N/A
- Revenue
- ATYR N/A
- POLE N/A
- Revenue This Year
- ATYR $1,264.26
- POLE N/A
- Revenue Next Year
- ATYR $1,239.11
- POLE N/A
- P/E Ratio
- ATYR N/A
- POLE $58.31
- Revenue Growth
- ATYR N/A
- POLE N/A
- 52 Week Low
- ATYR $1.42
- POLE $9.94
- 52 Week High
- ATYR $4.66
- POLE $11.16
- Technical
- Relative Strength Index (RSI)
- ATYR 77.04
- POLE N/A
- Support Level
- ATYR $4.16
- POLE N/A
- Resistance Level
- ATYR $3.94
- POLE N/A
- Average True Range (ATR)
- ATYR 0.30
- POLE 0.00
- MACD
- ATYR 0.13
- POLE 0.00
- Stochastic Oscillator
- ATYR 96.94
- POLE 0.00
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.